The startup has developed a medical device that targets and selectively removes galectin-3 from the bloodstream, addressing life-threatening conditions such as chronic kidney disease, organ fibrosis, and cancer. This technology provides physicians with effective treatment options for acute kidney injury, sepsis, and other inflammatory diseases.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sepsis and acute kidney injury (AKI) are critical global health challenges with high mortality rates and limited effective therapeutic options, resulting in significant healthcare costs. Current treatments primarily focus on stabilization rather than addressing the underlying causes of immune dysregulation, inflammation, and fibrosis. Elevated levels of galectin-3 (Gal-3) correlate with disease outcome in sepsis and AKI.
Solution
Eliaz Therapeutics offers the XGAL-3® device, a patented platform technology designed to selectively remove galectin-3 (Gal-3) from the bloodstream through targeted therapeutic apheresis. The XGAL-3 apheresis column contains a custom-designed molecule that efficiently binds and removes Gal-3 with high efficacy. By eliminating Gal-3, the device aims to reduce inflammation and fibrosis, improve patient outcomes, and potentially prevent long-term debilitating illnesses associated with sepsis and AKI. The device is designed for seamless integration with existing hospital apheresis systems.
Target Audience
The primary target audience includes hospitals and healthcare providers treating patients with sepsis and acute kidney injury (AKI).
Features
- Selective removal of galectin-3 (Gal-3) from the bloodstream
- Patented apheresis column with custom-designed Gal-3 binding molecule
- High efficacy in capturing and removing Gal-3
- Designed for seamless integration with existing hospital apheresis systems
- Single-use, disposable column for patient safety
- Aims to reduce inflammation and fibrosis associated with sepsis and AKI